C92.10

Chronic myeloid leukemia, BCR/ABL-positive, not having achieved remission

Chronic myeloid leukemia (CML) is a clonal myeloproliferative neoplasm characterized by the uncontrolled proliferation of myeloid cells. The hallmark of CML is the Philadelphia (Ph) chromosome, which results from a reciprocal translocation between chromosomes 9 and 22, t(9;22)(q34;q11). This translocation leads to the formation of the BCR-ABL fusion gene, encoding a constitutively active tyrosine kinase that drives the malignant transformation and proliferation of hematopoietic stem cells. The specific code C92.10 denotes BCR/ABL-positive CML in a state where remission has not been achieved. This means the disease is active and current treatment efforts have not led to a complete molecular or cytogenetic response, or a significant reduction in leukemic cells to define remission. CML typically progresses through three phases: chronic, accelerated, and blast crisis. Most patients are diagnosed in the chronic phase, which can last for years and is generally responsive to tyrosine kinase inhibitors (TKIs). However, 'not having achieved remission' indicates that despite therapy, the patient's disease remains active, necessitating ongoing treatment adjustments and close monitoring. Diagnostic confirmation relies on peripheral blood counts (often showing marked leukocytosis with a left shift), bone marrow examination (hypercellularity, increased granulopoiesis), and crucial cytogenetic or molecular testing to detect the Ph chromosome or BCR-ABL transcript (e.g., by FISH or PCR). Failure to achieve remission implies higher disease burden and potentially a less favorable prognosis compared to patients in remission, highlighting the need for intensive management strategies.

Clinical Symptoms

  • Fatigue
  • Weight loss
  • Night sweats
  • Abdominal discomfort due to splenomegaly
  • Early satiety
  • Anemia (pallor, shortness of breath, weakness)
  • Increased susceptibility to infections
  • Easy bruising or bleeding (less common, often in advanced phases)
  • Bone pain

Common Causes

  • Somatic mutation leading to the Philadelphia chromosome (BCR-ABL fusion gene)
  • Exposure to high-dose ionizing radiation (rare)

Documentation & Coding Tips

Explicitly state the BCR/ABL translocation status to justify the C92.1 category.

Example: Patient diagnosed with Chronic Myeloid Leukemia (CML) confirmed by FISH demonstrating t(9;22) translocation (BCR/ABL1 positive). Patient is currently in the chronic phase, however, BCR/ABL1 transcript levels remain at 5 percent on the International Scale after 6 months of Dasatinib therapy, indicating the patient has not achieved a major molecular remission. Active management continues with TKI therapy and monthly CBC monitoring.

Billing Focus: Documentation of the BCR/ABL status is mandatory for code specificity within the C92.1- series. Failure to specify BCR/ABL status may lead to the less specific C92.90 code, which is frequently targeted for documentation audits.

Clearly differentiate between not having achieved remission, in remission, and in relapse.

Example: Chronic myeloid leukemia, BCR/ABL-positive, not having achieved remission. Initial induction phase with Imatinib 400mg daily. Bone marrow biopsy at 3 months showed persistent Philadelphia chromosome-positive cells (45 percent). Patient remains on active treatment to achieve first complete cytogenetic response.

Billing Focus: The fifth character 0 specifically denotes not having achieved remission. This is clinically distinct from a patient who achieved remission and then relapsed (character 2) or is currently in remission (character 1).

Document the specific phase of CML as it informs the medical necessity for high-intensity treatments.

Example: 65-year-old male with BCR/ABL-positive CML, chronic phase, not having achieved remission. Physical exam reveals persistent splenomegaly 4cm below the costal margin. Labs show WBC of 45,000 with 2 percent blasts. Treatment plan involves switching from Imatinib to Nilotinib due to inadequate molecular response.

Billing Focus: While C92.10 covers the condition, documenting the phase (Chronic vs. Accelerated vs. Blast) supports the medical necessity of secondary or tertiary Tyrosine Kinase Inhibitors (TKIs) which are high-cost medications.

Link secondary manifestations like splenomegaly or anemia to the primary leukemia diagnosis.

Example: Patient presents with symptomatic anemia secondary to BCR/ABL-positive CML, not having achieved remission. Hgb 8.2, Hct 25. Splenomegaly documented on ultrasound. Fatigue is severe, limiting activities of daily living. Will initiate Epoetin alfa and continue CML targeted therapy.

Billing Focus: Coding manifestations separately while linking them in the clinical narrative provides a complete picture of the patient's acuity and justifies the use of supportive care codes (e.g., blood transfusions or growth factors).

Document the specific Tyrosine Kinase Inhibitor (TKI) and the patient's response or resistance patterns.

Example: BCR/ABL-positive CML, chronic phase, not having achieved remission. Patient has demonstrated T315I mutation on mutational analysis, indicating resistance to early-generation TKIs. Switching to Ponatinib 45mg daily. Close monitoring for cardiovascular adverse events required.

Billing Focus: Documentation of specific genetic mutations (like T315I) justifies the billing of high-complexity molecular pathology codes and expensive specialized pharmacotherapy.

Relevant CPT Codes

Related Diagnoses

Hierarchy